RU2013155480A - Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа - Google Patents
Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа Download PDFInfo
- Publication number
- RU2013155480A RU2013155480A RU2013155480/15A RU2013155480A RU2013155480A RU 2013155480 A RU2013155480 A RU 2013155480A RU 2013155480/15 A RU2013155480/15 A RU 2013155480/15A RU 2013155480 A RU2013155480 A RU 2013155480A RU 2013155480 A RU2013155480 A RU 2013155480A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical combination
- individual
- treated
- combination according
- mmol
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 12
- 239000008103 glucose Substances 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 235000012054 meals Nutrition 0.000 claims abstract 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960003105 metformin Drugs 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- 239000008280 blood Substances 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 230000037406 food intake Effects 0.000 claims abstract 2
- 235000012631 food intake Nutrition 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052 | 2011-05-13 | ||
| EP11166052.8 | 2011-05-13 | ||
| PCT/EP2012/058779 WO2012156312A1 (en) | 2011-05-13 | 2012-05-11 | Pharmaceutical combination for use in the treatment of diabetes type 2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017129878A Division RU2017129878A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013155480A true RU2013155480A (ru) | 2015-06-20 |
Family
ID=46052773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013155480/15A RU2013155480A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
| RU2017129878A RU2017129878A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017129878A RU2017129878A (ru) | 2011-05-13 | 2012-05-11 | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа |
Country Status (12)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| SG10201704716XA (en) * | 2013-01-17 | 2017-07-28 | Vtv Therapeutics Llc | Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| CA2932873A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| JP6641280B2 (ja) | 2014-01-09 | 2020-02-05 | サノフイＳａｎｏｆｉ | インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤 |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP4130005A4 (en) | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| CN115315426B (zh) | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| SI2324853T1 (sl) * | 2009-11-13 | 2015-12-31 | Sanofi-Aventis Deutschland Gmbh | Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2 |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en not_active Ceased
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko not_active Ceased
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX356728B (es) | 2018-06-12 |
| RU2017129878A (ru) | 2019-02-05 |
| US20130040878A1 (en) | 2013-02-14 |
| CA2835336A1 (en) | 2012-11-22 |
| JP6005140B2 (ja) | 2016-10-12 |
| AR086356A1 (es) | 2013-12-04 |
| KR20140041553A (ko) | 2014-04-04 |
| JP2014518860A (ja) | 2014-08-07 |
| WO2012156312A1 (en) | 2012-11-22 |
| BR112013029256A8 (pt) | 2018-01-16 |
| AU2012257780B2 (en) | 2017-06-01 |
| EP2709652A1 (en) | 2014-03-26 |
| CN103648519A (zh) | 2014-03-19 |
| BR112013029256A2 (pt) | 2016-11-29 |
| CN109045283A (zh) | 2018-12-21 |
| MX2013013198A (es) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017129878A (ru) | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа | |
| RU2013155473A (ru) | Фармацевтическая комбинация для применения для индуцирования потери массы тела у субъектов с диабетом 2 типа или/и для предотвращения набора массы тела у субъектов с диабетом 2 типа | |
| RU2014111821A (ru) | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа | |
| RU2013114376A (ru) | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа | |
| RU2013155474A (ru) | Ликсисенатид и метформин для лечения диабета типа 2 | |
| RU2014121386A (ru) | Протокол лечения диабета 2 типа | |
| RU2013155481A (ru) | Ликсисенатид в качестве дополнительной терапии к базальному инсулину при диабете 2 типа | |
| RU2013140403A (ru) | Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа | |
| RU2013148014A (ru) | Профилактика гипогликемии у пациентов с сахарным диабетом 2 типа | |
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| JP2017538705A5 (cg-RX-API-DMAC10.html) | ||
| JP2018503644A5 (cg-RX-API-DMAC10.html) | ||
| TW201105336A (en) | Combined medicine of pyrazole derivative and biguanide drug | |
| Smolensky et al. | Biological rhythms, drug delivery, and chronotherapeutics | |
| Sa et al. | Olanzapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome with rhabdomyolysis: a case report | |
| CA2944837A1 (en) | Cyclohexenyl compounds, compositions comprising them and uses thereof | |
| WO2019227764A1 (zh) | 一种mln4924在制备治疗糖尿病和/或肥胖药物的新用途 | |
| US8226990B2 (en) | Composition for treatment of diabetes mellitus and a preparation and an use thereof | |
| CN108938622B (zh) | 一种组合物及其在制备抗炎药物中的应用 | |
| JP2011105610A5 (cg-RX-API-DMAC10.html) | ||
| RU2014150946A (ru) | Способ снижения веса | |
| Kinoshita et al. | Regular Follow-up of olanzapine blood levels and impaired glucose tolerance in Olanzapine-induced diabetic ketoacidosis: a case report | |
| RU2545687C1 (ru) | Способ эрадикации хеликобактер пилори гастродуоденальной зоны | |
| CN111067910B (zh) | 一种用于预防和治疗糖尿病的药物组合物及其应用 | |
| Chua-See | DIABETIC STRIATOPATHY IN A NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS: A RARE NEUROLOGIC COMPLICATION |